180 related articles for article (PubMed ID: 34572958)
41. Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program.
Kollàr A; Maruzzo M; Messiou C; Cartwright E; Miah A; Martin-Liberal J; Thway K; McGrath E; Dunlop A; Khabra K; Seddon B; Dileo P; Linch M; Judson I; Benson C
Clin Sarcoma Res; 2014; 4():17. PubMed ID: 25905001
[TBL] [Abstract][Full Text] [Related]
42. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
[TBL] [Abstract][Full Text] [Related]
43. Characterization of Glioblastoma Cells Response to Regorafenib.
Mongiardi MP; Buccarelli M; Formato A; Orecchini E; Salbini M; Ricci V; Orsini T; Putti S; Chiesa S; Ricci-Vitiani L; D'Alessandris QG; Pallini R; Levi A; Falchetti ML
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551679
[TBL] [Abstract][Full Text] [Related]
44. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
Malmström A; Grønberg BH; Marosi C; Stupp R; Frappaz D; Schultz H; Abacioglu U; Tavelin B; Lhermitte B; Hegi ME; Rosell J; Henriksson R;
Lancet Oncol; 2012 Sep; 13(9):916-26. PubMed ID: 22877848
[TBL] [Abstract][Full Text] [Related]
45. [Results of postoperative radiochemotherapy of glioblastoma multiforme].
Lövey J; Fedorcsák I; Bajcsay A; Sipos L; Mangel L; Kásler M; Bagó A
Magy Onkol; 2013 Dec; 57(4):232-9. PubMed ID: 24353988
[TBL] [Abstract][Full Text] [Related]
46. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Vermorken JB; Clement PM; Gauler T; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Cohen EE;
Lancet Oncol; 2015 May; 16(5):583-94. PubMed ID: 25892145
[TBL] [Abstract][Full Text] [Related]
47. Regorafenib in patients with recurrent high-grade astrocytoma.
Kebir S; Rauschenbach L; Radbruch A; Lazaridis L; Schmidt T; Stoppek AK; Pierscianek D; Stuschke M; Forsting M; Sure U; Keyvani K; Kleinschnitz C; Scheffler B; Glas M
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1037-1042. PubMed ID: 30820715
[TBL] [Abstract][Full Text] [Related]
48. Long-term survival after glioblastoma resection: hope despite poor prognosis factors.
Costa E; Lawson TM; Lelotte J; Fomekong E; Vaz RG; Renard L; Whenham N; Raftopoulos C
J Neurosurg Sci; 2019 Jun; 63(3):251-257. PubMed ID: 29363298
[TBL] [Abstract][Full Text] [Related]
49. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
[TBL] [Abstract][Full Text] [Related]
50. Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).
Lombardi G; Pace A; Pasqualetti F; Rizzato S; Faedi M; Anghileri E; Nicolotto E; Bazzoli E; Bellu L; Villani V; Fabi A; Ferrazza P; Gurrieri L; Dall'Agata M; Eoli M; Della Puppa A; Pambuku A; D'Avella D; Berti F; Rudà R; Zagonel V
J Neurooncol; 2015 Nov; 125(2):359-67. PubMed ID: 26423801
[TBL] [Abstract][Full Text] [Related]
51. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
[TBL] [Abstract][Full Text] [Related]
52. Current evidence and challenges of systematic therapies for adult recurrent glioblastoma: Results from clinical trials.
Chen W; Liu D; Liu P; Kong Z; Wang Y; Wang Y; Ma W
Chin J Cancer Res; 2021 Jun; 33(3):417-432. PubMed ID: 34321837
[TBL] [Abstract][Full Text] [Related]
53. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
[TBL] [Abstract][Full Text] [Related]
54. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
[TBL] [Abstract][Full Text] [Related]
55. Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe).
Mrugala MM; Engelhard HH; Dinh Tran D; Kew Y; Cavaliere R; Villano JL; Annenelie Bota D; Rudnick J; Love Sumrall A; Zhu JJ; Butowski N
Semin Oncol; 2014 Oct; 41 Suppl 6():S4-S13. PubMed ID: 25213869
[TBL] [Abstract][Full Text] [Related]
56. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
[TBL] [Abstract][Full Text] [Related]
57. Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma.
Gleeson JP; Keane F; Keegan NM; Mammadov E; Harrold E; Alhusaini A; Harte J; Eakin-Love A; O'Halloran PJ; MacNally S; Hennessy BT; Breathnach OS; Grogan L; Morris PG
Cancer Med; 2020 Jan; 9(2):469-475. PubMed ID: 31756059
[TBL] [Abstract][Full Text] [Related]
58. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
[TBL] [Abstract][Full Text] [Related]
59. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract][Full Text] [Related]
60. A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer.
Kim RD; Sanoff HK; Poklepovic AS; Soares H; Kim J; Lyu J; Liu Y; Nixon AB; Kim DW
Cancer; 2020 Aug; 126(15):3464-3470. PubMed ID: 32453456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
